A Public Health Approach to Hepatitis C Control in Low- and Middle-Income Countries

Suthar, Amitabh B.; Harries, Anthony

doi:10.1371/journal.pmed.1001795

Cited by 35 publications

(31 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In cases in which such nonprogression can be anticipated by viral and host parameters, it may be justified to exclude some patients from aggressive interventions (Suthar and Harries, 2015;Casado et al, 2018). As a general rule, however, the potential benefits of early treatment are obvious not only to avoid disease on an individual basis, but also to diminish the chances of virus transmission (reviewed in Suthar and Harries, 2015; see also Sections 7.1 and 7.7 in Chapter 7 regarding the relevance of viral population numbers in transmission). Restricting the number of treated patients for economic reasons will result in more expensive public health interventions when infected individuals develop the disease.…”

Section: "Hit Early Hit Hard"mentioning

confidence: 99%

Quasispecies dynamics in disease prevention and control

Domingo

2020

Virus as Populations

View full text Add to dashboard Cite

Section: "Hit Early Hit Hard"mentioning

confidence: 99%

Quasispecies dynamics in disease prevention and control

Domingo

2020

Virus as Populations

View full text Add to dashboard Cite

“…Moreover, >95% of patients infected with viral hepatitis belong to a low-income population and/or are uninsured, and they cannot afford to pay the current market prices of DAAs (Figure 1). 27…”

Section: Hcv In Latin America: Burden Of Infection and Accessibility mentioning

confidence: 99%

Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals

Trinks

Caputo

Hulaniuk³

et al. 2017

PGPM

View full text Add to dashboard Cite

In recent years, great progress has been made in the field of new therapeutic options for hepatitis C virus (HCV) infection. The new direct-acting antiviral agents (DAAs) represent a great hope for millions of chronically infected individuals because their use may lead to excellent cure rates with fewer side effects. In Latin America, the high prevalence of HCV genotype 1 infection and the significant association of Native American ancestry with risk predictive single-nucleotide polymorphisms (SNPs) in IFNL4 and ITPA genes highlight the need to implement new treatment regimens in these populations. However, the universal accessibility to DAAs is still not a reality in the region as their high cost is one of the major, although not the only, limiting factors for their broad implementation. Therefore, under these circumstances, could the assessment of host genetic markers be a useful tool to prioritize DAA treatment until global access to these new drugs can be achieved? This review will summarize the scientific evidences and the potential implications of HCV pharmacogenomics in this rapidly evolving era of anti-HCV drug development.

show abstract

“…This is the case with elite controllers in the case of HIV-1 infection, and individuals infected with HCV who will not progress toward liver disease. In the cases in which such nonprogression can be anticipated by viral and host parameters, it may be justified to exclude some patients from aggressive interventions (Suthar and Harries, 2015). As a general rule, however, the potential benefits of early treatment are obvious not only to avoid disease on an individual basis, but also to diminish the chances of virus transmission (reviewed in Suthar and Harries, 2015; see also Sections 7.1 and 7.7 in Chapter 7 regarding the relevance of viral population numbers in transmission).…”

Section: "Hit Early Hit Hard"mentioning

confidence: 99%

“…In the cases in which such nonprogression can be anticipated by viral and host parameters, it may be justified to exclude some patients from aggressive interventions (Suthar and Harries, 2015). As a general rule, however, the potential benefits of early treatment are obvious not only to avoid disease on an individual basis, but also to diminish the chances of virus transmission (reviewed in Suthar and Harries, 2015; see also Sections 7.1 and 7.7 in Chapter 7 regarding the relevance of viral population numbers in transmission). Restricting the number of treated patients for economic reasons will result in more expensive public health interventions when the infected individuals develop disease.…”

Section: "Hit Early Hit Hard"mentioning

confidence: 99%